Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women

Maturitas

Volumn 56, Issue 1, 2007, Pages 38-44

  Messalli, Enrico M ^a   Mainini, Giampaolo ^a   Scaffa, Cono ^a   Cafiero, Angela ^a   Salzillo, Pier Luigi ^a   Ragucci, Angelo ^a   Cobellis, Luigi ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Menopause; Osteoporosis; Osteoprotegerin; Raloxifene

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; RALOXIFENE;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PROTEIN BINDING; FEMALE; HUMAN; MENOPAUSAL SYNDROME; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

BONE DENSITY; COLLAGEN; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OSTEOBLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33845402400     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.05.007     Document Type: Article

References (43)

1. Luisetto G., Zangari M., Tizian L., et al. Influence of aging and menopause in determining vertebral and distal forearm bone loss in adult healthy women. Bone Miner 22 (1993) 9-25
2. Riggs B.L., Khosla S., and Melton III L.J. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13 (1998) 763-773
3. Compston J.E. Sex steroids and bone. Physiol Rev 81 (2001) 419-447
4. Cheung J., Mak Y.T., Papaioannoul S., Evans B.A.J., Fogelman I., and Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-β oestradiol and raloxifene. J Endocrinol 177 (2003) 423-433
5. Liao E.Y., Luo X.H., and Su X. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest 25 (2002) 785-790
6. Viereck V., Grundker C., Blaschke S., et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 88 (2003) 4206-4213
7. Taranta A., Brama M., Teti A., et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 (2002) 368-376
8. Oh K.W., Rhee E.J., Lee W.Y., et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol (Oxf) 61 2 (2004 Aug) 244-249
9. Hofbauer L.C., Kuhne C.A., and Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4 3 (2004 Sep) 268-275
10. Bashir A., Mak Y.T., Sankaralingam S., et al. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 70 (2005) 847-855
11. Scheidt-Nave C., Bismar H., Leidig-Bruckner G., et al. Serum Interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 86 (2001) 2032-2042
12. Manolagas S.C., and Jilka R.L. Bone marrow, cytokines, and bone remodelling. Emerging insights into the path physiology of osteoporosis. N Engl J Med 332 (1995) 305-311
13. Riggs B.L., and Melton L.J. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 171 (2002) 11-14
14. Wüster C., Albanese C., De Aloysio D., et al., The Phalangeal Osteosonogrammetry Study Group. Phalangeal osteosonogrammetry study: age-related changes, diagnostic sensitivity, and discrimination power. J Bone Miner Res 15 (2000) 1603-1613
15. Riggs B.L., Khosla S., Atkinson E.J., Dunstan C.R., and Melton III L.J. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporos Int 14 (2003) 728-733
16. Bord S., Ireland D.C., Beavan S.R., and Compston J.E. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32 (2003) 136-141
17. Oleksik A.M., Duong T., Pliester N., Asma G., Popp-Snijders C., and Lips P. Effects of the selective estrogen receptor modulator, raloxifene on the somatotropic axis insulin-glucose homeostasis. J Clin Endocrinol Metab 86 (2001) 2763-2768
18. Xing L., and Boyce B.F. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 328 (2005) 709-720
19. Koka S., Petro T.M., and Reinhardt R.A. Estrogen inhibits interleukin-1 beta-induced interleukin-6 production by human osteoblast-like cells. J Interferon Cytokine Res 18 (1998) 479-483
20. Secreto F.J., Grover A., Pacurari M., et al. Estrogen potentiates the combined effects of transforming growth factor-beta and tumor necrosis factor-alfa on adult human osteoblast-like cell prostaglandin E2 biosynthesis. Calcif Tissue Int 73 (2003) 565-574
21. Mizuno A., Amizuka N., Irie K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247 (1998) 610-615
22. Yano K., Tsuda E., Washida N., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14 (1999) 518-527
23. Ueland T., Bollerslev J., Godang K., Muller F., Froland S.S., and Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 145 (2001) 685-690
24. Mazziotti G., Sorvillo F., Piscopo M., et al. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 20 3 (2005 Mar) 480-486
25. Mezquita-Raya P., de la Higuera M., Garcia D.F., et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 16 11 (2005 Nov) 1368-1374
26. Han K.O., Choi J.T., Choi H.A., et al. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin Endocrinol (Oxf) 62 3 (2005 Mar) 349-353
27. Hegedus D., Ferencz V., Lakatos P.L., et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res 17 11 (2002 Nov) 1961-1967
28. Delmas P.D., Eastell R., Garnero P., and Seibel J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int Suppl 6 (2000) S2-S17
29. Million Women Study (MWS). Breast cancer and hormone replacement therapy in the Million Women study Collaborators. The Lancet 302 (2003) 419-427
30. Writing group for the Women's Health Initiative (WHI) investigators. Risks and benefits of estrogen plus progestin in health postmenopausal: principal results from Women's Health Initiative Randomized Controlled Trial. JAMA 288 (2002) 321-333
31. Bell N.H. Vitamin D metabolism, aging, and bone loss. J Clin Endocrinol Metab 80 (1995) 1051
32. Siris E., Adachi J.D., Lu Y., et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple outcomes of raloxifene evaluation. Osteoporos Int 13 (2002) 907-913
33. The North American Menopause Society (NAMS). Management of postmenopausal osteoporosis. Position statement. Menopause 9 (2002) 84-101
34. Li J., Tang J.G., Wu H.Y., and Wu W.K. Effect of raloxifene and estradiol on the biological function and osteoprotegerin expression of osteoblasts in vitro. Di Yi Jun Yi Da Xue Xue Bao 25 7 (2005) 787-790
35. Lindberg M.K., Erlandsson M., Alatalo S.L., et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation if the OPG/RANKL (osteoprotegerin/receptor activator of NF-Kappa B ligand) ratio and serum interleukin-6 in male mice. J Endocrinol 171 (2001) 425-433
36. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., and Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 (1999) 4367-4370
37. Rogers A., Saleh G., Hannon R.A., Greenfield D., and Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87 10 (2002) 4470-4475
38. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., Willvonseder R., and Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in healthy adult population. Bone 32 (2003) 681-686
39. Reginster J.Y., Henrotin Y., Christiansen C., et al. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 69 3 (2001) 130-137
40. Rosen H.N., Moses A.C., Garber J., et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66 2 (2000) 100-103
41. Srivastava A.K., Vliet E.L., Lewiecki E.M., et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 21 7 (2005) 1015-1026
42. Tauchmanova L., Nuzzo V., Del Puente A., et al. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre-and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas 48 (2004) 299-306
43. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16 2 (2001) 348-360